New combo therapy aims to fight recurrent brain tumors
NCT ID NCT02800486
First seen May 02, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This phase 2 trial tests a combination of a targeted cancer drug (cetuximab) given directly into the brain's blood vessels along with repeat radiation for people whose brain cancer has come back. The study includes 37 adults with specific types of aggressive brain tumors that overproduce a protein called EGFR. The goal is to see if this approach can safely slow tumor growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lenox Hill Brain Tumor Center
RECRUITINGNew York, New York, 10075, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cetuximab (Erbitux) and radiation therapy
What this could lead to
If successful, this could offer a new treatment option for patients with recurrent brain cancer, potentially slowing tumor growth and extending survival.
What could go wrong
This is a small, early-phase trial (37 people) with no control group, so results may not apply broadly. The treatment involves radiation and a targeted drug, which can cause side effects like brain swelling or toxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.